The Immunoscore, which is based on densities of CD3+ and cytotoxic CD8+ T cells in the tumor and invasive margin, was originally validated as a predictive estimate of the risk of recurrence in patients with stage I–III colon cancer [31] and has since been included in several clinical guidelines. The gene discussed is CD8A; the disease is neoplasm.